Caricamento...
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
INTRODUCTION: As a result of the new treatment paradigm that the haemophilia community will face with the availability of novel (non‐factor) therapies, an updated consensus on ITI recommendations and inhibitor management strategies is needed. AIM: The Future of Immunotolerance Treatment (FIT) group...
Salvato in:
| Pubblicato in: | Haemophilia |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6850066/ https://ncbi.nlm.nih.gov/pubmed/31033112 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13762 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|